3 results
Search Results
2. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases.
- Author
-
Gehl, Julie, Sersa, Gregor, Matthiessen, Louise Wichman, Muir, Tobian, Soden, Declan, Occhini, Antonio, Quaglino, Pietro, Curatolo, Pietro, Campana, Luca G., Kunte, Christian, Clover, A. James P., Bertino, Giulia, Farricha, Victor, Odili, Joy, Dahlstrom, Karin, Benazzo, Marco, and Mir, Lluis M.
- Subjects
- *
CANCER treatment , *METASTASIS , *ANTINEOPLASTIC agents , *CANCER chemotherapy , *CELL membranes , *DECISION making , *ELECTROTHERAPEUTICS , *SKIN tumors , *OPERATIVE surgery , *TREATMENT effectiveness , *TUMOR treatment - Abstract
Electrochemotherapy is now in routine clinical use to treat cutaneous metastases of any histology, and is listed in national and international guidelines for cutaneous metastases and primary skin cancer. Electrochemotherapy is used by dermatologists, surgeons, and oncologists, and for different degrees and manifestations of metastases to skin and primary skin tumours not amenable to surgery. This treatment utilises electric pulses to permeabilize cell membranes in tumours, thus allowing a dramatic increase of the cytotoxicity of anti-cancer agents. Response rates, often after only one treatment, are very high across all tumour types. The most frequent indications are cutaneous metastases from malignant melanoma and breast cancer. In 2006, standard operating procedures (SOPs) were written for this novel technology, greatly facilitating introduction and dissemination of the therapy. Since then considerable experience has been obtained treating a wider range of tumour histologies and increasing size of tumours which was not originally thought possible. A pan-European expert panel drawn from a range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and oncology met to form a consensus opinion to update the SOPs based on the experience obtained. This paper contains these updated recommendations for indications for electrochemotherapy, pretreatment information and evaluation, treatment choices, as well as follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Post-transplant Merkel Cell Carcinoma.
- Author
-
KOLJONEN, Virve, SAHI, Helka, BÖHLING2, Tom, and MÄKISALO3, Heikki
- Subjects
- *
MERKEL cell carcinoma , *DRUG side effects , *IMMUNOSUPPRESSIVE agents , *TRANSPLANTATION of organs, tissues, etc. , *CANCER treatment , *SKIN cancer , *THERAPEUTICS - Abstract
Malignant tumours are the foremost complications of immunosuppressive treatment. They are a major challenge for organ transplant recipients and their treating physicians. This paper reviews the aetiology and current treatment of an unusual neuroendocrine skin cancer, Merkel cell carcinoma (MCC), caused by a Merkel cell polyomavirus infection. MCC occurs more frequently than expected in immunosuppressed subjects, especially in organ transplant recipients. The current literature comprises reports of 79 organ transplant recipients with MCC. The risk of MCC in organ transplant recipients is increased up to 66-182-fold compared with the general population. In addition to the increased risk of developing MCC, immunosuppressed individuals have poorer MCC-specific survival. The aim of this review article is to familiarize organ transplant doctors with this unique and clinically challenging skin cancer, and to provide recent data on the diagnosis and current treatment recommendations for an immunosuppressed population. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.